Clin2
NCT06992999Possibly a fitNot yet recruiting

Psilocybin for treating OCD

Obsessive - Compulsive Disorder

Part of Mental health clinical trials.

This study tests if a single dose of psilocybin, a psychedelic substance, can safely help people with obsessive-compulsive disorder (OCD) who have not responded well to standard treatments. If you have moderate to severe OCD and have tried at least one recommended treatment without success, you may be able to join.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
20 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be 18 years or older.
  • You have been diagnosed with OCD that is at least moderately severe.
  • You have tried at least one standard OCD treatment that did not work well enough.
  • You must stop taking certain medications or supplements, including most antidepressants and other psychedelics, for at least 2 weeks before the study (6 weeks for fluoxetine).
  • You cannot have a current substance use problem or a personal or family history of psychosis.
  • You must be in generally good physical health and not have conditions that raise safety risks, such as uncontrolled high blood pressure or heart problems.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07347405Recruiting· Phase 1
Psilocybin Whole Mushroom for OCD Treatment

This trial tests a whole-mushroom version of psilocybin as a potential treatment for OCD that hasn't improved with standard therapies. Participants receive psilocybin in a controlled setting and are monitored closely for safety and changes in symptoms.

Tucson, Arizona
NCT04882839Recruiting· Phase 2
Therapy with psilocybin for severe OCD symptoms

This Phase 2 study tests whether psilocybin-assisted psychotherapy can reduce symptoms in adults with severe, treatment-resistant OCD. It also focuses on safety and whether this approach is practical to run.

Beersheba
NCT05783817Recruiting· Phase 2
MDMA-assisted therapy for OCD in adults

This trial tests whether MDMA plus cognitive behavioral therapy (CBT) can reduce OCD symptoms in adults who have tried standard OCD treatments before. You may be asked to pause certain medicines and follow specific diet/medication rules around the study session.

Palo Alto, California
NCT04539951Recruiting· Phase 2
Trial for newly treated obsessive-compulsive disorder

This phase 2 study tests an OCD treatment strategy for people who have not yet had OCD medications or recent OCD therapy. It aims to reduce OCD symptoms, especially for those with moderate-to-severe symptom levels.

Shanghai, Shanghai Municipality
NCT07111988Not yet recruiting· Phase 2
Valbenazine for obsessive-compulsive disorder

This study tests whether a medication called valbenazine can help reduce symptoms of moderate to severe OCD in adults. If you have OCD and are not currently changing your treatment, you may be able to join and see if this new approach works for you.

NCT06442423Recruiting· Phase 1
Psilocybin study for people with psychiatric symptoms

This trial tests if psilocybin, a substance found in certain mushrooms, can help people with various mental health symptoms that affect daily life. You would take a single dose in a supervised setting and be monitored for changes in your mood and well-being.

New Haven, Connecticut

Hear when a new Obsessive-Compulsive Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.